Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of Pembrolizumab Combined With Anlotinib and Chemotherapy Neoadjuvant Therapy of Locally Advanced Gastric Cancer

NCT05385900 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT05385900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05385900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of Pembrolizumab Combined With Anlotinib and Chemotherapy Neoadjuvant Therapy of Locally Advanced Gastric Cancer
Lead sponsor
Xijing Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
June 30, 2022
Completion date
June 30, 2024
Enrollment
57 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer